ISLET Act
- Bill Number
- H.R. 8018
- Origin Chamber
- House
- Congress
- 119th Congress, Session 2
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2026-03-19: Referred to the House Committee on Energy and Commerce.
- Last Updated
- 2026-06-12T13:42:45Z
AI-Generated Summary
Purpose
The ISLET Act (Increase Support for Life-saving Endocrine Transplantation Act) aims to classify human cadaveric islets—clusters of insulin-producing cells taken from the pancreases of deceased donors—for transplantation as organs, similar to whole pancreases. This supports life-saving transplants, primarily for people with severe type 1 diabetes.
Key Provisions
- Amendment to Public Health Service Act: Adds "human cadaveric islets" to the list of items regulated as organs for transplantation (under 42 U.S.C. 274b(d)(2)).
- Clarifications on Definitions:
- Excludes human cadaveric islets from being classified as a drug (under the Federal Food, Drug, and Cosmetic Act).
- Excludes them from being a biological product (under the Public Health Service Act).
- Excludes them from HCT/Ps (human cells, tissues, or cellular or tissue-based products, regulated by FDA under lighter rules for minimally processed items).
- Regulatory Actions:
- Secretary of Health and Human Services (HHS) must update relevant regulations (under Public Health Service Act parts F, G, H and Federal Food, Drug, and Cosmetic Act) within 1 year of enactment.
- HHS must submit a progress report to Congress within 6 months of enactment.
Significant Changes to Existing Law
- Shifts regulation of cadaveric islets from potential FDA oversight as drugs, biologics, or HCT/Ps (which involve clinical trials, manufacturing standards, or tissue rules) to the organ transplant system managed by the Organ Procurement and Transplantation Network (OPTN).
- Removes ambiguity, ensuring islets are treated like pancreases rather than processed tissues or drugs.
Potential Impacts
- Government Agencies: HHS and FDA must revise rules, potentially streamlining approvals; reduces FDA's drug/biologic workload.
- Citizens: Improves access to islet transplants for diabetes patients by easing regulatory barriers, possibly increasing availability and reducing costs/delays.
- International Relations: Minimal direct impact, though it may influence global standards for organ/tissue transplants.
Main Stakeholders Affected
- Patients: People with type 1 diabetes needing islet transplants to restore insulin production.
- Healthcare Providers: Transplant centers and surgeons performing islet procedures.
- Organ Procurement Organizations: Groups like OPTN that allocate organs from deceased donors.
- Donor Families: Those consenting to pancreas/islet donation.
- Government: HHS, FDA, and Congress overseeing implementation.
Notable Legal, Constitutional, or Political Implications
- Legal: Clarifies jurisdiction, preventing overlapping FDA and organ regulations; supports public health goals without new funding mandates.
- Constitutional: No apparent issues; aligns with Congress's authority over interstate commerce and public health.
- Political: Bipartisan sponsorship (Reps. Norman and Bacon); promotes innovation in diabetes treatment amid organ shortage debates, potentially setting precedent for other tissue transplants.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (5)
Rep. Bacon, Don [R-NE-2], Rep. Mann, Tracey [R-KS-1], Rep. Gill, Brandon [R-TX-26], Rep. LaLota, Nick [R-NY-1], Rep. Garbarino, Andrew R. [R-NY-2]
Recent Actions
- 2026-03-19: Referred to the House Committee on Energy and Commerce.
- 2026-03-19: Introduced in House
- 2026-03-19: Introduced in House
Bill Versions
- Increase Support for Life-saving Endocrine Transplantation Act — issued 2026-03-19 — PDF (3 pages)